0001133416-23-000073.txt : 20230918
0001133416-23-000073.hdr.sgml : 20230918
20230918095344
ACCESSION NUMBER: 0001133416-23-000073
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230915
FILED AS OF DATE: 20230918
DATE AS OF CHANGE: 20230918
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEWIS JOEL
CENTRAL INDEX KEY: 0001725595
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31791
FILM NUMBER: 231260304
MAIL ADDRESS:
STREET 1: 12575 ULINE DRIVE
CITY: PLEASANT PRAIRIE
STATE: WI
ZIP: 53158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC
CENTRAL INDEX KEY: 0001133416
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043562325
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD
STREET 2: SUITE 240
CITY: NORCROSS
STATE: GA
ZIP: 30071
BUSINESS PHONE: 678-620-3186
MAIL ADDRESS:
STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD
STREET 2: SUITE 240
CITY: NORCROSS
STATE: GA
ZIP: 30071
FORMER COMPANY:
FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20010612
4
1
form4.xml
X0508
4
2023-09-15
0001133416
GALECTIN THERAPEUTICS INC
GALT
0001725595
LEWIS JOEL
C/O GALECTIN THERAPEUTICS INC.
4960 PEACHTREE INDUSTRIAL BLVD., STE 240
NORCROSS
GA
30071
true
true
President and CEO
false
Common Stock
2023-09-15
4
A
0
10947
1.76
A
969405
D
Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units ("DSUs") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024.
Represents shares underlying DSUs and Common Stock.
Jack W. Callicutt, by power of attorney
2023-09-18